In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Completed

• Conditions: Essential Hypertension

• Registration Number: NCT00802542
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2008-12-04
• Study First Submitted QC: 2008-12-04
• Study First Posted: 2008-12-05
• Primary Completion: 2009-01
• Study Completion: 2009-01
• Status Verified: 2010-12
• Last Update Submitted: 2010-12-02
• Last Update Posted: 2010-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided
• Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria

• Hypersensitivity to the active substance or to any of the excipients of Atacand.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Decrease in blood pressure	once after 4 weeks

Trial Locations

Locations (2)

Research site; 🇱🇻 Liepaja, Latvia

Research Site; 🇱🇻 Riga, Latvia